55results about How to "Reduce arrhythmia" patented technology

Radiosurgical treatments of tissues of the heart mitigate arrhythmias and treat other tumerous and non-tumerous disease using an implanted fiducial positioned in or near the heart using cardiac catheterization techniques. The fiducials may be implanted after diagnostic and planning images of the target tissues have been acquired. Fiducial implantation may take place the day of a scheduled radiosurgical treatment. Techniques to accommodate post-planning fiducial implantation may include registration of the implanted fiducial location with the treatment plan, and active fiducials may limit collateral imaging radiation exposure while enhancing tracking accuracy.

The present invention is directed to monoclonal antibodies and fragments thereof directed to LRP5/6 that find use in the prevention and treatment of cardiac remodeling and cancer. Also disclosed are methods for using such monoclonal antibodies in the prevention and treatment of such diseases.

The invention discloses new application of sodium houttuyfonate in pharmacy, in particular to the application of the sodium houttuyfonate in preparing medicaments for preventing and treating myocardial hypertrophy and/or ventricular hypertrophy. The application is to prepare an in-vitro myocardial cell hypertrophyby adopting three methods of preparing an in-vivo animal model of myocardial hypertrophy and ventricular hypertrophy, culturing a myocardial cell in vitro and inducing epinephrine by isoproterenol, L-thyroxine and abdominal aorta banding. Experiment results prove that the sodium houttuyfonate can reduce the increase of left cardiac index and global cardiac index of a model animal, inhibit hypertrophy of an in-vitro myocardial cell, reduce the cAMP concentration of plasma, the content of Ang II and ET-1 of a myocardial tissue and the content of TNF-alpha and ALD of serum, and can reduce blood pressure and decrease heart rate. Experiment results suggest that the sodium houttuyfonate has the functions of resisting myocardial hypertrophy and ventricular hypertrophy, and the mechanism of the sodium houttuyfonate can be related to the inhibition of sympathetic activity, blockage of system activity of feritin-hypertensin-aldosterone, and effect of endocrine factors.

The invention discloses a traditional Chinese preparation used for treating myocardial infarction caused by myocardial ischemia which comprises the following traditional Chinese materials with the weight account: ginseng of 17 to 22, water frog of 8 to 12, schisandra of 8 to 12, aconite of 8 to 12, salvia of 8 to 12, platyciad semen of 18 to 22, gadfly of 8 to 12, pinellia ternate of 8 to 12, panax notoginseng of 8 to 12, ligusticum wallichii of 8 to 12, musk of 0.8 to 1.2, melon of 13 to 17, Chinese onion of 13 to 17. The invention has the advantages of replenishing qi, activating blood and eliminating phlegm, treating myocardial infarction caused by myocardial ischemia by combining with the western medicine treatment, and reducing the incidence of arrhythmia, pump failure, embolization and other complications obviously; intravenous thromboly treatment significantly lowers the hospitalized death rate.

The present invention provides for methods and compositions for treating and/or preventing cardiac dysfunction by administering to subject a therapeutically effective amount of a bisphosphonate, functional analogue or a pharmaceutically effective salt thereof.

The invention discloses a natural galenical preparation helping promote dam lactation, which consists of the following raw materials in part by weight: 1 to 6 parts of pawpaw extract, 2 to 4 parts of danshen extract, 1 to 3 parts of white tea extract, 1 to 3 parts of poplar flower extract, 1 to 4 parts of hawthorn extract, 1 to 3 parts of astragalus extract, 1 to 3 parts of pine extract, and 2 to 6 parts of carrier. The preparation method comprises the following steps: respectively extracting pine, pawpaw, danshen, white tea, poplar flower, hawthorn and astragalus; and mixing and stirring the prepared dry powder and the carrier in proportion at normal temperature and under normal pressure to prepare the natural galenical preparation helping promote dam lactation. The natural galenical preparation has the effects of lactation promotion, iron supply, blood and nutrition supply, has no medicament residue, no toxic or side effect, promotes newborn animals to be weaned earlier, improves uniformity degree of the newborn animals, and prolongs the life of rare wild animals.

A catheter for delivery of contrast material for a medical imaging procedure, the catheter comprising: (a) an operative distal head comprising a tubular body including at least two turns and characterized by a transverse proximal aspect that is larger than a transverse distal aspect; and (b) a plurality of contrast material ports distributed along said tubular body between at least two of said at least two turns.

The invention relates to a technology of skin nourishing and protecting, particularly relates to traditional Chinese medicinal anti-senile wrinkle-removing whitening spot-removing acne-removing facial mask powder, and a preparation method and using method thereof, and belongs to the field of medicaments. The facial mask powder is prepared from the following raw materials in parts by weight: 5-25 parts of radix ginseng alba, 5-20 parts of bletilla striata, 5-20 parts of Chinese yam, 5-25 parts of radix paeoniae alba, 5-20 parts of ussuriensis fritillary bulb, 5-25 parts of cortex dictamni, 5-15 parts of apricot, 5-15 parts of ginkgo nut, 5-30 parts of semen coicis, 5-10 parts of pearl powder, 5-20 parts of talc powder, 1-5 parts of peppermint and 5-15 parts of rhizoma kaempferiae. The using method comprises the following steps: weighing 5-8g of facial mask powder; putting the facial mask powder into a container, and mixing with egg white to obtain paste; and applying the paste to a required position on the skin for 40-80 minutes, and cleaning the facial mask powder on the skin with clean water. By using the facial mask powder, the skin and mental states of a user can achieve an excellent state which cannot be achieved by the user self before, and the skin can be bright, moistened and white, and fine wrinkles can be removed.

The invention relates to a remote monitoring and early warning system of heart rates in group sports. The remote monitoring and early warning system is characterized by comprising wearable devices, acloud server and a remote heart rate monitoring system; the wearable devices are used for monitoring heart rate data of individuals, the wearable devices send the monitored heart rate data to the cloud server, and the remote heart rate monitoring system is used for collecting the heart rate data of the cloud server in real time, processing the data and carrying out early warning in real time. By means of the remote monitoring and early warning system, the heart rate information monitored by the wearable devices can be sent to the cloud server, terminal devices can collect the data of all the individuals and carry out early warning feedback in real time, it can be achieved that the heart rates in the group sports are integrally collected and early warning is carried out in real time, the problems of arrhythmia even sudden death in the group sports are effectively avoided, and the remote monitoring and early warning system can be widely used for heart rate monitoring of large group sports.

The invention relates to a tablet composition containing enalapril and folic acid and a preparation method thereof. The tablets prepared by the preparation method are capable of effectively reducing the degradation of active ingredients of a medicine while improving the stability and safety of a compound solid preparation as well as the disintegration rate and timeliness of the medicine in the stomach and intestines; the composition meets the dosage requirements for accurate absorption, and the therapeutic effect of the medicine is remarkably improved.

The invention provides an application of hexachlorophene in the preparation of a KCNQ agonist. In addition, the invention provides an application of the hexachlorophene in the preparation of a medicine serving as the KCNQ agonist. In the application, the KCNQ agonist can be a KCNQ1 agonist, a KCNQ1/KCNE1 agonist, a KCNQ2 agonist or KCNQ2/KCNQ3 agonist. The hexachlorophene has the effects of shortening the action potential duration and treating the arrhythmia by boosting KCNQ1/KCNE1 electric currents and promoting the repolarization of the action potential of myocardial cells. The subtype potentiation proves that the hexachlorophene is capable of enhancing KCNQ and M electric currents and has the effects of adjusting the membrane potential level by boosting KCNQ2 electric currents and KCNQ2/KCNQ3 hetero-oligomer electric currents and weakening the issuing frequency of the action potential; the application of the hexachlorophene in the preparation of medicines taking KCNQ as anti-epileptic targets is realized, and the anti-epileptic effect is achieved.

The 10-23 deoxyribozyme constructed in the invention utilizes in-vitro-transcription ET-1 full-length RNA as s substrate to filter the 10-23 deoxyribozyme with cut ET-1 mRNA, and can reduce the expression of an ET-1 gene of myocardial cells through transfection, inhibit hypertrophy of serum induced myocardial cells, and reduce the damage of hypoxic myocardial cells; the ET-1 10-23 deoxyribozyme can obviously reduce the occurrence of arrhythmia of isolated rat hearts after acute ischemia and improve heart functions. The invention provides tools for further clearing the functions of endogenous ET-1 in acute ischemic arrhythmia, and also provides theoretical basis and new ways of thinking for explaining the mechanism and prevention of and development of new medicaments for the acute ischemic arrhythmia.

The present invention inter alia relates to a method of promoting collateral circulation comprising the step of exposing a subject to a therapeutically effective amount of an NO donor wherein the therapeutically effective amount of the NO donor promotes arteriogenesis sufficient to augment collateral circulation in a physiological or pathological condition.

The present invention relates to methods and pharmaceutical compositions for cardioprotection of subjects who experienced a myocardial infarction. In particular, the present invention relates to a ligand of the sonic hedgehog signaling pathway for use in the cardioprotection of a subject who experienced a myocardial infarction.